Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards
This study demonstrates the feasibility and clinical utility of integrating genomic-driven precision oncology with PDOX-based functional testing for MPNSTs. This strategy may support molecular tumor boards (MTBs) in their treatment decisions. The observed genomic stability supports the use of longitudinal tumor profiling to guide treatment, and the success of MEKi+BETi highlights its potential as a combination therapy for MPNSTs.
Authors
- Miriam Magallón‐Lorenz (ORCID: https://orcid.org/0000-0003-2741-4572)
- Moira Garraus (ORCID: https://orcid.org/0000-0002-8049-9221)
- C Lázaro
- Juana Fernández‐Rodríguez (ORCID: https://orcid.org/0000-0002-7760-5804)
- Meritxell Carrió (ORCID: https://orcid.org/0000-0002-1258-6593)
- Alberto Villanueva
- Alicia Castañeda
- Helena Mazuelas
- Eduard Serra
- Hector Salvador
- Itziar Uriarte-Arrazola
- Edgar Creus-Bachiller
- Carlota Rovira
- Mariana Alvarez
- Bernat Gel
- Sara Ortega-Bertran
Institutions
- Hospital Sant Joan de Déu Barcelona (ES)
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Departament de Salut (ES)
- Ajuntament de L’Hospitalet (ES)
- Institut Català d'Oncologia (ES)
- Institute for Research in Biomedicine (ES)
- Sant Joan de Déu Research Foundation (ES)
- Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1186/s12967-026-07751-9
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00